<?xml version="1.0" encoding="UTF-8"?>
<p id="Par46">The anti-malaria drug hydroxychloroquine has also been investigated for its ability to inhibit viral infections
 <sup>
  <xref ref-type="bibr" rid="CR200">200</xref>
 </sup>. However, available evidence does not support a beneficial effect of hydroxychloroquine over standard therapy in treating mild-to-moderate disease
 <sup>
  <xref ref-type="bibr" rid="CR201">201</xref>
 </sup>, nor as a post-exposure prophylaxis strategy
 <sup>
  <xref ref-type="bibr" rid="CR202">202</xref>
 </sup>. Moreover, two clinical trials have shown that hydroxychloroquine treatment poses serious safety concerns, increasing the risk of cardiovascular death by more than twofold
 <sup>
  <xref ref-type="bibr" rid="CR203">203</xref>,
  <xref ref-type="bibr" rid="CR204">204</xref>
 </sup>. Given the lack of definitive proof of efficacy for any of these drugs in patients with COVID-19, caution is warranted, particularly when the use of these compounds prevents the use of other, life-saving treatments for concurrent conditions.
</p>
